1797 related articles for article (PubMed ID: 18759925)
1. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
2. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
5. The B7/CD28 costimulatory family in autoimmunity.
Keir ME; Sharpe AH
Immunol Rev; 2005 Apr; 204():128-43. PubMed ID: 15790355
[TBL] [Abstract][Full Text] [Related]
6. How the immune system achieves self-nonself discrimination during adaptive immunity.
Jiang H; Chess L
Adv Immunol; 2009; 102():95-133. PubMed ID: 19477320
[TBL] [Abstract][Full Text] [Related]
7. From cancer immunosurveillance to cancer immunotherapy.
Stagg J; Johnstone RW; Smyth MJ
Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade in cancer immunotherapy.
Korman AJ; Peggs KS; Allison JP
Adv Immunol; 2006; 90():297-339. PubMed ID: 16730267
[TBL] [Abstract][Full Text] [Related]
9. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
[TBL] [Abstract][Full Text] [Related]
10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
11. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
Cheuk AT; Mufti GJ; Guinn BA
Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5238-42. PubMed ID: 17875750
[TBL] [Abstract][Full Text] [Related]
13. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily.
Peggs KS; Allison JP
Br J Haematol; 2005 Sep; 130(6):809-24. PubMed ID: 16156851
[TBL] [Abstract][Full Text] [Related]
14. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
16. Anatomy of the immune system: facts and problems.
Grossi CE; Ciccone E; Tacchetti C; Santoro G; Anastasi G
Ital J Anat Embryol; 2000; 105(4):97-124. PubMed ID: 11265217
[TBL] [Abstract][Full Text] [Related]
17. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
18. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
19. The B7 family and cancer therapy: costimulation and coinhibition.
Zang X; Allison JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5271-9. PubMed ID: 17875755
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
